Skip to content
    Qiming Venture Partners USA logo

    Qiming Venture Partners USA

    Cambridge, Massachusetts, United StatesFounded 2017
    www.qimingvcusa.comLinkedIn
    HealthcareBiotech & Life Sciences

    Qiming Venture Partners USA is a healthcare-focused venture capital firm founded in 2017 as the US arm of the China-based Qiming Venture Partners. The firm partners with innovative entrepreneurs to build transformative therapies and healthcare technologies, and has raised over $550 million across three funds.

    58% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (49% of deals). Average disclosed round size is $68.9M (across 40 rounds with reported amounts).

    Find people at Qiming Venture Partners USA on Goldilocks AI

    Portfolio

    29

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    3

    Team

    Gary Rieschel

    Gary Rieschel

    Managing Partner

    Mark McDade

    Mark McDade

    Managing Partner

    David Chu

    David Chu

    Operating Partner

    Robert Headley

    Robert Headley

    Operating Partner

    Will McConnell

    Will McConnell

    Partner

    Emma Sacher

    Emma Sacher

    Executive Assistant & Operations

    Holly Schlichting

    Holly Schlichting

    Executive Assistant & Operations

    Laurel Brakus

    Laurel Brakus

    Executive Assistant & Operations

    Ryan Baker

    Ryan Baker

    Chief Financial Officer

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    43 investments
    CompanyRoundAmountDate
    Tenpoint Therapeutics logoTenpoint TherapeuticsSeries B—Jan 2026
    DDualitasSeries A$65MSep 2025
    Dualitas Therapeutics logoDualitas TherapeuticsSeries A$65MSep 2025
    Rhino Federated Computing logoRhino Federated ComputingSeries A$15MMay 2025
    Umoja logoUmojaSeries C$100MJan 2025
    Umoja Biopharma logoUmoja BiopharmaSeries C$100MJan 2025
    Dualitas Therapeutics logoDualitas TherapeuticsSeries A$65MJan 2025
    Rhino Federated Computing logoRhino Federated ComputingUnknown$15MJan 2025
    SSoda HealthSeries B$50MDec 2024
    Ventyx Biosciences logoVentyx BiosciencesSeries A$27MSep 2024
    Tenpoint Therapeutics logoTenpoint TherapeuticsSeries A$70MJul 2023
    Abdera Therapeutics Inc. logoAbdera Therapeutics Inc.Series B—Apr 2023
    Abdera Therapeutics Inc. logoAbdera Therapeutics Inc.Series A$142MApr 2023
    AAbderaSeries B$110MApr 2023
    Abdera Therapeutics logoAbdera TherapeuticsSeries B$110MJan 2023
    Tenpoint Therapeutics logoTenpoint TherapeuticsSeries A$70MJan 2023
    Entact Bio logoEntact BioSeries A$81MDec 2022
    Entact logoEntactSeries A$81MDec 2022
    SSoda HealthSeries A$25MSep 2022
    Auron Therapeutics logoAuron TherapeuticsSeries A$48MJul 2022
    Abdera Therapeutics Inc. logoAbdera Therapeutics Inc.Series B—Jan 2022
    Entact Bio logoEntact BioSeries A$81MJan 2022
    Entact logoEntactSeries A$81MJan 2022
    Ventyx Biosciences logoVentyx BiosciencesSeries B$51MSep 2021
    HilleVax logoHilleVaxUnknown$135MSep 2021
    Page 1 of 2

    Top Co-Investors

    venBio11 shared
    Cormorant Asset Management8 shared
    Alexandria Venture Investments7 shared
    Surveyor Capital7 shared
    MPM Capital6 shared
    Versant Ventures6 shared
    Viking Global Investors5 shared
    Abingworth LLP5 shared
    Logos Capital5 shared
    F-Prime Capital4 shared
    Sofinnova Partners4 shared
    Eight Roads4 shared
    DCVC4 shared
    Arkin Bio Ventures4 shared
    Eli Lilly and Company4 shared
    Lightspeed Venture Partners4 shared
    RTW Investments, LP4 shared
    Scale Venture Partners3 shared
    GG13 shared
    Vivo Capital3 shared

    Last updated: 7 October 2026